We are harnessing RNA payloads (RNAi, mRNA, saRNA, and cirRNA) as in vivo tools for drug discovery.
Nucleic acids loaded lipid nanoparticles have emerged as a promising therapeutic approach for various malignancies, rare genetic diseases, and inflammation. We aim to utilize RNA-loaded lipid nanoparticles to identify in vivo (in their biological environment) new potential drug targets that could be then applied to therapeutics in various malignancies, including head & neck cancer, glioblastoma, blood cancers, breast cancer, rare genetic diseases, and inflammation-related diseases such as inflammatory bowel diseases (IBD)
